A Quality Improvement Program to Reduce Potential Overtreatment of Diabetes Among Veterans at High Risk of Hypoglycemia

Background.. Intensive glycemic control confers increased risk of hypoglycemia and little benefit among older individuals with diabetes. The aim of this quality improvement project was to reduce the number of patients treated to A1C levels that might confer greater risk than benefit (i.e., potential overtreatment) in the VA New England Healthcare System. Methods.. A provider report and clinical reminder were created to identify potentially overtreated patients and prompt clinicians to consider treatment de-intensification. Potentially overtreated patients were defined as those on insulin or a sulfonylurea whose most recent A1C was <7.0% and who were >74 years of age or diagnosed with dementia or cognitive impairment. The numbers of patients screened and whose treatment was de-intensified using the clinical reminder were counted from January to December 2014. The number of high-risk veterans at baseline was compared with that 6 and 18 months after implementation using t tests. Results.. A total of 2,830 patients were screened using the clinical reminder; 9.6% had their glycemic treatment de-intensified. Among the 261 patients reporting hypoglycemia, 37% had their treatment de-intensified. Higher percentages of patients had treatment de-intensified when reported symptoms were more severe. The monthly average in the high-risk cohort declined from baseline by 18% at 6 months and by 22% at 18 months (both P <0.005). Conclusions.. A clinical reminder helps clinicians identify and reduce the number of potentially overtreated patients. The large number of screened patients whose treatment was not de-intensified suggests that a clinical reminder should be combined with provider education, national guidelines, and performance measures aligned in the interest of reducing potential overtreatment.

[1]  Fawn M. Wolf,et al.  Standards of Medical Care in Diabetes—2016 Abridged for Primary Care Providers , 2016, Clinical Diabetes.

[2]  S. Saini,et al.  Rates of Deintensification of Blood Pressure and Glycemic Medication Treatment Based on Levels of Control and Life Expectancy in Older Patients With Diabetes Mellitus. , 2015, JAMA internal medicine.

[3]  B. Zikmund‐Fisher,et al.  Appropriate Prescribing for Patients With Diabetes at High Risk for Hypoglycemia: National Survey of Veterans Affairs Health Care Professionals. , 2015, JAMA internal medicine.

[4]  M. Fine,et al.  Tight Glycemic Control and Use of Hypoglycemic Medications in Older Veterans With Type 2 Diabetes and Comorbid Dementia , 2015, Diabetes Care.

[5]  Harlan M Krumholz,et al.  National trends in US hospital admissions for hyperglycemia and hypoglycemia among Medicare beneficiaries, 1999 to 2011. , 2014, JAMA internal medicine.

[6]  D. Aron,et al.  Assessing potential glycemic overtreatment in persons at hypoglycemic risk. , 2014, JAMA internal medicine.

[7]  Kenneth D Mandl,et al.  Participatory surveillance of hypoglycemia and harms in an online social network. , 2013, JAMA internal medicine.

[8]  S. Inzucchi,et al.  Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364–1379 , 2013, Diabetes Care.

[9]  A. J. Green,et al.  Self-reported hypoglycemia and impact on quality of life and depression among adults with type 2 diabetes mellitus. , 2012, Diabetes research and clinical practice.

[10]  D. Matthews,et al.  Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach , 2012, Diabetes Care.

[11]  V. Basevi,et al.  Standards of Medical Care in Diabetes—2012 , 2011, Diabetes Care.

[12]  D. Aron,et al.  Choosing Targets for Glycaemia, Blood Pressure and Low-Density Lipoprotein Cholesterol in Elderly Individuals with Diabetes Mellitus , 2011, Drugs & aging.

[13]  L. Pogach,et al.  Risk of Hypoglycemia in Older Veterans with Dementia and Cognitive Impairment: Implications for Practice and Policy , 2011, Journal of the American Geriatrics Society.

[14]  C. Richards,et al.  Emergency hospitalizations for adverse drug events in older Americans. , 2011, The New England journal of medicine.

[15]  Mark Woodward,et al.  Severe hypoglycemia and risks of vascular events and death. , 2010, The New England journal of medicine.

[16]  M. Chin,et al.  The Effect of Comorbid Illness and Functional Status on the Expected Benefits of Intensive Glucose Control in Older Patients with Type 2 Diabetes: A Decision Analysis , 2008, Annals of Internal Medicine.

[17]  Diederick Grobbee,et al.  Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. , 2008, The New England journal of medicine.

[18]  N. Clark,et al.  Standards of Medical Care in Diabetes: Response to Power , 2006 .

[19]  Bradley N Doebbeling,et al.  Variation in implementation and use of computerized clinical reminders in an integrated healthcare system. , 2004, The American journal of managed care.

[20]  Donald R. Miller,et al.  Who has diabetes? Best estimates of diabetes prevalence in the Department of Veterans Affairs based on computerized patient data. , 2004, Diabetes care.

[21]  Qian Rong-l,et al.  A better comprehension of “Management of Hyperglycemia in Type 2 Diabetes:A Patient-Centered Approach—Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)” , 2013 .

[22]  S. Schinner Effects of Intensive Glucose Lowering in Type 2 Diabetes , 2009 .

[23]  B. Hemmelgarn,et al.  Anti-diabetic drug use and the risk of motor vehicle crash in the elderly. , 2006, The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique.

[24]  T. J. Moore,et al.  Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. , 2007, Archives of internal medicine.